India’s MDRF and Russia’s Almazov Centre Join Forces for AI-Powered Diabetes Research
 |
| Iamge credit: The Hindu |
Chennai | May 23, 2025: In a major boost to global medical cooperation, India’s Madras Diabetes Research Foundation (MDRF) has signed a strategic memorandum of understanding (MoU) with Russia’s Almazov National Medical Research Centre, based in Saint Petersburg. The partnership aims to fast-track innovation in diabetes diagnosis, treatment, and prevention — with a strong focus on gestational diabetes and the emerging potential of artificial intelligence (AI) and precision medicine.
Global Vision for a Shared Challenge
The MoU was officially signed by Dr. V. Mohan, Chairman of MDRF, and Professor Evgeny Shlyakhto, Director-General of the Almazov Centre. Both institutions are recognized leaders in the field of endocrinology and metabolic disorders.
“This collaboration reflects our shared commitment to tackling diabetes through scientific innovation and global cooperation,” said Dr. Mohan. “AI and precision medicine offer exciting possibilities to improve care and patient outcomes.”
Key Areas of Collaboration
According to an official press release, the partnership will focus on:
- Joint research projects, including ongoing work on gestational diabetes mellitus (GDM)
- AI-driven diagnostic tools for early detection and personalized treatment
- Academic exchange programmes for medical professionals and researchers
- Collaborative scientific publications
- Capacity-building through joint training programmes
The agreement is not limited to theoretical research — clinical applications and translational outcomes are a clear priority.
AI in the Spotlight at Saint Petersburg Forum
Highlighting the importance of digital innovation in healthcare, Dr. V. Mohan delivered a keynote address on the role of artificial intelligence in diabetes management at the 8th Saint Petersburg Medical Innovation Forum, hosted at the Almazov Centre. His talk emphasized how AI is revolutionizing real-time patient monitoring, predictive analytics, and early diagnosis.
As part of the collaboration, research teams led by Polina V. Popova from Almazov and experts from MDRF have already begun joint studies on gestational diabetes. This area is particularly crucial in India, where GDM poses serious risks to maternal and neonatal health.
A Path Forward in Global Health Innovation
This Indo-Russian alliance marks a significant milestone in cross-border scientific partnerships at a time when chronic diseases like diabetes are becoming global epidemics. The emphasis on technology-powered solutions, especially AI and precision medicine, signals a forward-thinking approach to managing one of the world’s fastest-growing health burdens.
As the collaboration unfolds, experts expect to see breakthroughs that could reshape diabetes care, not only in India and Russia, but worldwide.
